A Director at Exelixis (NASDAQ: EXEL) is Selling SharesBy Carrie Williams
Following Charles Cohen’s last EXEL Sell transaction on January 05, 2016, the stock climbed by 16.5%. In addition to Charles Cohen, 7 other EXEL executives reported Sell trades in the last month.
Based on Exelixis’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $77.58 million and quarterly net profit of $35.12 million. In comparison, last year the company earned revenue of $9.94 million and had a GAAP net loss of $43.64 million. The company has a one year high of $23.49 and a one year low of $3.55. The Company has a book value per share of 70.5684.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $24.00, reflecting a -9.4% downside.
The insider sentiment on Exelixis has been negative according to 28 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exelixis, Inc. is a biopharmaceutical company, which engages in the developing and commercializing small molecule therapies for the treatment of cancer. Its brands include COMETRIQ and cobimetinib. The company focuses on their proprietary resources and development and commercialization of cabozantinib. Exelixis was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in South San Francisco, CA.